Ovarian Cancer News

Mom, 37, Saw Doctor 10 Times for Pain That Was Dismissed as a Hernia, Until a Female Doctor Took Her Seriously - People.com

Mom, 37, Saw Doctor 10 Times for Pain That Was Dismissed as a Hernia, Until a Female Doctor Took Her Seriously People.com

Antibody–drug conjugates in gynaecological cancers: opportunities and challenges - Nature

Antibody–drug conjugates in gynaecological cancers: opportunities and challenges Nature

Monmouthshire mum says she may have avoided ovarian cancer if she lived in England - BBC

Monmouthshire mum says she may have avoided ovarian cancer if she lived in England BBC

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study - Yahoo Finance

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study Yahoo Finance

IIQ: Results due within 13 days...? - Next Investors

IIQ: Results due within 13 days...? Next Investors

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Yahoo Finance

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip Yahoo Finance

New ovarian cancer treatment approved for NHS - the first for 20 years - Sky News

New ovarian cancer treatment approved for NHS - the first for 20 years Sky News

Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer - OncLive

Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer OncLive

Targeting CDH6: A New ADC Approach in Gynecologic Cancer - Cancer Nursing Today

Targeting CDH6: A New ADC Approach in Gynecologic Cancer Cancer Nursing Today

Nanowire device captures ovarian cancer biomarkers from blood serum - Oncology Central

Nanowire device captures ovarian cancer biomarkers from blood serum Oncology Central

TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026 - PR Newswire

TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026 PR Newswire

Weill Cornell Medicine Scientist Receives Award for Research on New Ovarian Cancer Targets - WCM Newsroom

Weill Cornell Medicine Scientist Receives Award for Research on New Ovarian Cancer Targets WCM Newsroom

Christel Paganoni-Bruijns: World Ovarian Cancer Coalition Seeks Global Director of Communications - Oncodaily

Christel Paganoni-Bruijns: World Ovarian Cancer Coalition Seeks Global Director of Communications Oncodaily

St. Luke’s Physician Is Climbing High to Support Ovarian Cancer Patients - Bucks County Herald newspaper

St. Luke’s Physician Is Climbing High to Support Ovarian Cancer Patients Bucks County Herald newspaper

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin® - Yahoo Finance

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin® Yahoo Finance

‘How I knew I had endometrial cancer’: Survivors share their stories - UT MD Anderson

‘How I knew I had endometrial cancer’: Survivors share their stories UT MD Anderson

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer - Nature

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer Nature

A Common Cholesterol Drug May Weaken Ovarian Cancer Spread - Duke Today

A Common Cholesterol Drug May Weaken Ovarian Cancer Spread Duke Today

Cedars-Sinai Launches New Cayton BRCA Center | Newswise - Newswise

Cedars-Sinai Launches New Cayton BRCA Center | Newswise Newswise

Compugen spotlights COM701 ovarian trial at ESMO congress - Stock Titan

Compugen spotlights COM701 ovarian trial at ESMO congress Stock Titan

Johnson & Johnson wins talc bellwether trial over ovarian cancer claims - Class Action Lawsuits

Johnson & Johnson wins talc bellwether trial over ovarian cancer claims Class Action Lawsuits

Context Therapeutics Reports 29% Response Rate for CTIM-76 in Platinum-Resistant Ovarian Cancer Phase 1 Trial - BioPharm International

Context Therapeutics Reports 29% Response Rate for CTIM-76 in Platinum-Resistant Ovarian Cancer Phase 1 Trial BioPharm International

Circulating Immune Protein Signature Is Validated as OS Prognostic Tool in Recurrent Ovarian Cancer - OncLive

Circulating Immune Protein Signature Is Validated as OS Prognostic Tool in Recurrent Ovarian Cancer OncLive

Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer - OncLive

Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer OncLive

From Ovarian to Endometrial Cancer, Experts Spotlight Standout Data From ASCO 2026 - OncLive

From Ovarian to Endometrial Cancer, Experts Spotlight Standout Data From ASCO 2026 OncLive

Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire

Allarity Therapeutics to Present Trial-in-Progress Poster GlobeNewswire

Adiposity and cancer: systematic review and meta-analysis - Nature

Adiposity and cancer: systematic review and meta-analysis Nature

Ovarian Carcinosarcoma With Heterologous Chondrosarcomatous Differentiation: A Case Report and Review of Literature - Cureus

Ovarian Carcinosarcoma With Heterologous Chondrosarcomatous Differentiation: A Case Report and Review of Literature Cureus